163 related articles for article (PubMed ID: 38443692)
1. Cutaneous toxicities of mitogen-activated protein kinase inhibitors in children and young adults with neurofibromatosis-1.
Peacock BC; Tripathy S; Hanania HL; Wang HY; Sadighi Z; Patel AB
J Neurooncol; 2024 May; 167(3):515-522. PubMed ID: 38443692
[TBL] [Abstract][Full Text] [Related]
2. Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.
Dombi E; Baldwin A; Marcus LJ; Fisher MJ; Weiss B; Kim A; Whitcomb P; Martin S; Aschbacher-Smith LE; Rizvi TA; Wu J; Ershler R; Wolters P; Therrien J; Glod J; Belasco JB; Schorry E; Brofferio A; Starosta AJ; Gillespie A; Doyle AL; Ratner N; Widemann BC
N Engl J Med; 2016 Dec; 375(26):2550-2560. PubMed ID: 28029918
[TBL] [Abstract][Full Text] [Related]
3. Selumetinib in Children with Inoperable Plexiform Neurofibromas.
Gross AM; Wolters PL; Dombi E; Baldwin A; Whitcomb P; Fisher MJ; Weiss B; Kim A; Bornhorst M; Shah AC; Martin S; Roderick MC; Pichard DC; Carbonell A; Paul SM; Therrien J; Kapustina O; Heisey K; Clapp DW; Zhang C; Peer CJ; Figg WD; Smith M; Glod J; Blakeley JO; Steinberg SM; Venzon DJ; Doyle LA; Widemann BC
N Engl J Med; 2020 Apr; 382(15):1430-1442. PubMed ID: 32187457
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of Mek Inhibitors in the Treatment of Plexiform Neurofibromas: A Retrospective Study.
Cacchione A; Fabozzi F; Carai A; Colafati GS; Baldo GD; Rossi S; Diana M; Megaro G; Milano GM; Macchiaiolo M; Crocoli A; De Ioris MA; Boccuto L; Secco DE; Zama M; Agolini E; Tomà P; Mastronuzzi A
Cancer Control; 2023; 30():10732748221144930. PubMed ID: 36598023
[TBL] [Abstract][Full Text] [Related]
5. MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus.
de Blank PMK; Gross AM; Akshintala S; Blakeley JO; Bollag G; Cannon A; Dombi E; Fangusaro J; Gelb BD; Hargrave D; Kim A; Klesse LJ; Loh M; Martin S; Moertel C; Packer R; Payne JM; Rauen KA; Rios JJ; Robison N; Schorry EK; Shannon K; Stevenson DA; Stieglitz E; Ullrich NJ; Walsh KS; Weiss BD; Wolters PL; Yohay K; Yohe ME; Widemann BC; Fisher MJ
Neuro Oncol; 2022 Nov; 24(11):1845-1856. PubMed ID: 35788692
[TBL] [Abstract][Full Text] [Related]
6. NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.
Weiss BD; Wolters PL; Plotkin SR; Widemann BC; Tonsgard JH; Blakeley J; Allen JC; Schorry E; Korf B; Robison NJ; Goldman S; Vinks AA; Emoto C; Fukuda T; Robinson CT; Cutter G; Edwards L; Dombi E; Ratner N; Packer R; Fisher MJ
J Clin Oncol; 2021 Mar; 39(7):797-806. PubMed ID: 33507822
[TBL] [Abstract][Full Text] [Related]
7. Plexiform neurofibroma: shedding light on the investigational agents in clinical trials.
Acar S; Armstrong AE; Hirbe AC
Expert Opin Investig Drugs; 2022 Jan; 31(1):31-40. PubMed ID: 34932916
[TBL] [Abstract][Full Text] [Related]
8. Selumetinib for plexiform neurofibromas in neurofibromatosis type 1: a single-institution experience.
Espírito Santo V; Passos J; Nzwalo H; Carvalho I; Santos F; Martins C; Salgado L; Silva CE; Vinhais S; Vilares M; Salgado D; Nunes S
J Neurooncol; 2020 Apr; 147(2):459-463. PubMed ID: 32108293
[TBL] [Abstract][Full Text] [Related]
9. Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas.
Armstrong AE; Belzberg AJ; Crawford JR; Hirbe AC; Wang ZJ
BMC Cancer; 2023 Jun; 23(1):553. PubMed ID: 37328781
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous reactions in children treated with MEK inhibitors, BRAF inhibitors, or combination therapy: A multicenter study.
Boull CL; Gardeen S; Abdali T; Li E; Potts J; Rubin N; Carlberg VM; Gupta D; Hunt R; Luu M; Maguiness SM; Moertel CL; Song H; Vivar KL; Coughlin C; Huang JT; Lara-Corrales I
J Am Acad Dermatol; 2021 Jun; 84(6):1554-1561. PubMed ID: 32682884
[TBL] [Abstract][Full Text] [Related]
11. The Use of MEK Inhibitors in Neurofibromatosis Type 1-Associated Tumors and Management of Toxicities.
Klesse LJ; Jordan JT; Radtke HB; Rosser T; Schorry E; Ullrich N; Viskochil D; Knight P; Plotkin SR; Yohay K
Oncologist; 2020 Jul; 25(7):e1109-e1116. PubMed ID: 32272491
[TBL] [Abstract][Full Text] [Related]
12. Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.
Fisher MJ; Shih CS; Rhodes SD; Armstrong AE; Wolters PL; Dombi E; Zhang C; Angus SP; Johnson GL; Packer RJ; Allen JC; Ullrich NJ; Goldman S; Gutmann DH; Plotkin SR; Rosser T; Robertson KA; Widemann BC; Smith AE; Bessler WK; He Y; Park SJ; Mund JA; Jiang L; Bijangi-Vishehsaraei K; Robinson CT; Cutter GR; Korf BR; ; Blakeley JO; Clapp DW
Nat Med; 2021 Jan; 27(1):165-173. PubMed ID: 33442015
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics and exposure-response of selumetinib and its N-desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas.
Schalkwijk S; Zhou L; Cohen-Rabbie S; Jain L; Freshwater T; So K; He Z; Gioni I; Tomkinson H; Vishwanathan K; Zhou D
Cancer Chemother Pharmacol; 2021 Aug; 88(2):189-202. PubMed ID: 33903938
[TBL] [Abstract][Full Text] [Related]
14. Incidence of Ophthalmological Complications in NF-1 Patients Treated with MEK Inhibitors.
Hummel L; Ameri M; Alqahtani S; Sadighi Z; Al-Zubidi N
Curr Oncol; 2024 May; 31(5):2644-2649. PubMed ID: 38785480
[TBL] [Abstract][Full Text] [Related]
15. French cohort of children and adolescents with neurofibromatosis type 1 and symptomatic inoperable plexiform neurofibromas: CASSIOPEA study.
Wolkenstein P; Chaix Y; Entz Werle N; Amini-Adle M; Barbarot S; Boileau C; Miled A; Rashid T; Aerts I
Eur J Med Genet; 2023 May; 66(5):104734. PubMed ID: 36868501
[TBL] [Abstract][Full Text] [Related]
16. Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial.
Robertson KA; Nalepa G; Yang FC; Bowers DC; Ho CY; Hutchins GD; Croop JM; Vik TA; Denne SC; Parada LF; Hingtgen CM; Walsh LE; Yu M; Pradhan KR; Edwards-Brown MK; Cohen MD; Fletcher JW; Travers JB; Staser KW; Lee MW; Sherman MR; Davis CJ; Miller LC; Ingram DA; Clapp DW
Lancet Oncol; 2012 Dec; 13(12):1218-24. PubMed ID: 23099009
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Plexiform Neurofibromas with MEK Inhibitors: First Results with a New Therapeutic Option.
Vaassen P; Dürr NR; Rosenbaum T
Neuropediatrics; 2022 Feb; 53(1):52-60. PubMed ID: 34905788
[TBL] [Abstract][Full Text] [Related]
18. Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas.
Kim A; Gillespie A; Dombi E; Goodwin A; Goodspeed W; Fox E; Balis FM; Widemann BC
Neurology; 2009 Oct; 73(16):1273-9. PubMed ID: 19841379
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.
Widemann BC; Babovic-Vuksanovic D; Dombi E; Wolters PL; Goldman S; Martin S; Goodwin A; Goodspeed W; Kieran MW; Cohen B; Blaney SM; King A; Solomon J; Patronas N; Balis FM; Fox E; Steinberg SM; Packer RJ
Pediatr Blood Cancer; 2014 Sep; 61(9):1598-602. PubMed ID: 24753394
[TBL] [Abstract][Full Text] [Related]
20. Novel molecular targeted therapies for patients with neurofibromatosis type 1 with inoperable plexiform neurofibromas: a comprehensive review.
Solares I; Viñal D; Morales-Conejo M; Rodriguez-Salas N; Feliu J
ESMO Open; 2021 Aug; 6(4):100223. PubMed ID: 34388689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
